The phrase "activating point" is correct and usable in written English.
It can be used in contexts where you are referring to a specific moment or location that triggers an action or process.
Example: "The activating point for the experiment was when the temperature reached 100 degrees Celsius."
Alternatives: "triggering point" or "activation moment".
In distinction to activating point mutations, pathway activation through PIK3CA gene dosage effects following low level genomic amplification have also been described [ 38].
The feasibility of inducing point mutations in tumor suppressor genes and oncogenes in the liver was also demonstrated by co-injection of Cas9-sgRNA plasmids targeting β-catenin and a single-stranded DNA oligonucleotide donor carrying activating point mutations, resulting in hepatocytes with activation of β-catenin localizing in the nucleus [ 25].
It is now known that activating point mutations in components of the mitogen-activated protein kinase pathway commonly occur in melanoma.
The V617F activating point mutation in Jak2 is associated with a proportion of myeloproliferative disorders.
However, activating point mutations in breast columnar cell lesions have been infrequently studied.
Activating point mutations in PIK3CA are found in 25%to30%0% of invasive breast cancers; however, they have not previously been investigated in radial scars.
We screened papillary breast neoplasms for activating point mutations in PIK3CA, AKT1, and RAS protein-family members, which are common in invasive ductal carcinomas.
Here we modelled human lung adenocarcinoma, which frequently harbours activating point mutations in KRAS and inactivation of the p53 pathway, using conditional alleles in mice.
Activating point mutations in the phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) are among the most common molecular defects in invasive breast cancer.
While activating point mutations in PIK3CA (encoding phosphatidylinositol-3-kinase catalytic subunit) or AKT1 are found in 25%to30%0% of invasive ductal carcinomas, the mutational profile of invasive micropapillary carcinomas has not been characterized in detail.
Duplication of the BRAF locus has been reported as the most frequent aberration in pediatric LGAs (66% [18]), whereas activating point mutations in BRAF occur less commonly (4 6%) [22], [23].
